Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 1
2020 1
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umaña P. Bacac M, et al. Among authors: limani f. Clin Cancer Res. 2018 Oct 1;24(19):4785-4797. doi: 10.1158/1078-0432.CCR-18-0455. Epub 2018 May 1. Clin Cancer Res. 2018. PMID: 29716920 Free article.
Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining In Vitro Experiments with Systems Modeling.
Van De Vyver AJ, Weinzierl T, Eigenmann MJ, Frances N, Herter S, Buser RB, Somandin J, Diggelmann S, Limani F, Lehr T, Bacac M, Walz AC. Van De Vyver AJ, et al. Among authors: limani f. Mol Cancer Ther. 2021 Feb;20(2):357-366. doi: 10.1158/1535-7163.MCT-20-0269. Epub 2020 Dec 9. Mol Cancer Ther. 2021. PMID: 33298591
The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
Palazzo A, Herter S, Grosmaire L, Jones R, Frey CR, Limani F, Bacac M, Umana P, Oldham RJ, Marshall MJE, Cox KL, Turaj AH, Cragg MS, Klein C, Carter MJ, Tannheimer S. Palazzo A, et al. Among authors: limani f. J Immunol. 2018 Apr 1;200(7):2304-2312. doi: 10.4049/jimmunol.1700323. Epub 2018 Feb 16. J Immunol. 2018. PMID: 29453281 Free PMC article.